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Background: Association of melanoma, neural system tumors and germ line mutations at the 9p21 region in the
CDKN2A, CDKN2B and CDKN2BAS genes has been reported in a small number of families worldwide and described
as a discrete syndrome in melanoma families registered as a rare disease, the melanoma–astrocytoma syndrome.
Case presentation: We here studied two young patients developing melanoma after radiotherapy for astrocytoma,
both reporting lack of family history for melanoma or neural system tumors at genetic counselling. Patient A is a
girl treated for anaplastic astrocytoma at 10 years and for multiple melanomas on the scalp associated to dysplastic
nevi two years later. Her monozygotic twin sister carried dysplastic nevi and a slow growing, untreated cerebral
lesion. Direct sequencing analysis showed no alterations in melanoma susceptibility genes including CDKN2A, CDK4,
MC1R and MITF or in TP53. By microsatellite analysis, multiplex ligation-dependent probe amplification, and array
comparative genomic hybridization a deletion including the CDKN2A, CDKN2B and CDKN2BAS gene cluster was
detected in both twin sisters, encompassing a large region at 9p21.3 and occurring de novo after the loss of one
paternal allele.
Patient B is a boy of 7 years when treated for astrocytoma then developing melanoma associated to congenital
nevi on the head 10 years later: sequencing and multiplex ligation-dependent probe amplification revealed a
normal profile of the CDKN2A/CDKN2B/CDKN2BAS region. Array comparative genomic hybridization confirmed the
absence of deletions at 9p21.3 and failed to reveal known pathogenic copy number variations.
Conclusions: By comparison with the other germ line deletions at the CDKN2A, CDKN2B and CDKN2BAS gene
cluster reported in melanoma susceptible families, the deletion detected in the two sisters is peculiar for its de novo
origin and for its extension, as it represents the largest constitutive deletion at 9p21.3 region identified so far.
In addition, the two studied cases add to other evidence indicating association of melanoma with exposure to
ionizing radiation and with second neoplasm after childhood cancer. Melanoma should be considered in the
monitoring of pigmented lesions in young cancer patients.
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The combination of melanoma and neural system tu-
mors (NST) was described in melanoma families where
the diseases occurred in different family members or
concomitantly, and was registered as a rare disease, the
melanoma-astrocytoma syndrome (OMIM 155755).
Three families from France, UK and USA showing as-
sociation of melanoma, NST and germ line deletions of
part or of the entire CDKN2A locus, as well as of
CDKN2B and the non-coding CDKN2BAS genes, have
been described [1-3]. In other studies, families prone to
melanoma and NST lacked deletions in the 9p21 region,
although other altered loci causing the syndrome have
not been identified [4-7]. Missense mutations in CDKN2A
genes were also described in one French and two Italian
families reporting melanoma associated with meningioma
and neuroblastoma respectively [8,9]. The analysis of
other genes located in this region, such as KLHL9 and
PTPRD, failed to identify inherited mutations in melan-
oma and NST kindreds [7,10].
While the genetic basis for NST remains largely un-
identified [11], several genes associated to melanoma
predisposition besides CDKN2A have been recently identi-
fied [12].
In a recent study we genetically characterized a series
of 21 pediatric melanoma treated at our Institute [13]:
two cases developing melanoma after NST were studied
for deletions at the 9p21 region. Here we report the re-
sults of these analyses.
Case presentation
We report the case of a female Italian patient (A) treated
for anaplastic astrocytoma (10 yr) who developed multiple
melanomas on the scalp associated to dysplastic nevi two
years later (Figure 1). In the following 8 years when she
was followed clinically at our Institute, she developed 10
melanomas on the head, neck, trunk and leg. She also de-
veloped neurotechoma (8 yr) and neurofibroma (18 yr). AFigure 1 Histopathology of the initial biopsy specimens excised from
patient revealing a superficial spreading melanoma with epithelioid appear
of melanocytic nevi (B). Hematoxylin and eosin, magnification 10×.tectal mesencephalic lesion growing along 10 years and
producing hydrocephalus was the final reason for her
death (20 yr). Her monozygotic twin sister (TS) carried
dysplastic nevi and a slow growing, untreated cerebral le-
sion at parietal cortex (22 yr). The pedigree profile at gen-
etic counselling lacked neoplastic diseases in the maternal
lineage while in the paternal lineage an uncle and his son
had unspecified neoplastic disease.
The sequencing analysis showed wild type sequences
for CDKN2A, CDK4, and MC1R; in addition, TP53 mu-
tations and the MITF E318K variant identified in familial
melanoma [14,15] were not found (data not shown) (see
Additional file 1: Methods). The allele status of microsat-
ellite markers in the CDKN2A gene region was analyzed
in patient A, her parents and TS (see Additional file 2:
Table S1). For the markers D9S974, D9S942, D9S1748
and D9S1749 a single peak was detected for the patient
and the TS, while for the parents two alleles with at least
one allele of the same size were shown. For each marker,
the allele found had the same size of one of the maternal
allele (see Additional file 3: Figure S1) indicating the oc-
currence of a deletion in the CDKN2A locus in the pater-
nal allele.
Multiplex Ligation-dependent Probe Amplification
(MLPA) showed hemizygosity of CDKN2A-CDKN2B
gene region for patient A and TS, and normal profiles
for the parents (see Additional file 4: Figure S2), support-
ing a de novo origin. The analysis of metaphase chromo-
somes from EBV-immortalized lymphocytes by FISH
hybridization using as probe the C5 cosmid spanning
about 50 kb of the chromosomal region from CDKN2A to
CDKN2B genes further confirmed the deletion in the two
sisters (data not shown). Oligo array-comparative genomic
hybridization (aCGH) analysis was performed to confirm
MLPA results and to better define the deletion break-
points. The analysis of ratio profiles revealed for patient A
and TS a deletion at the 9p21.3 chromosomal region of
approximately 2,135 Mb including part of the CDKN2BASthe head of patient A. Specimens from the head neoplasms of the
ance associated with a compound nevus (inset) (A) or in the absence
Figure 2 Schematic representation of the deletion identified in patient A and of germ line deletions at the 9p21.3 region reported in
other studies. A. Array-CGH 400K ratio profile: on the left, the chromosome ideogram, on the right, the log2 ratio of chromosome 9 probes
plotted as a function of chromosomal position. Probes with a value zero represent equal fluorescence intensity ratio between sample and
reference DNAs; each filled rectangle represents a single probe spotted on the array. Copy number losses shift the ratio to negative log ratio
values. In the lower part, the deleted region at 9p21.3 detected in patient A is shown in red and the deleted genes are represented according to
UCSC Genome Browser (NCBI build 37, hg19). The deleted region spans between oligomers at 19,934,142 Mb (A_18_P26451569, first deleted)
and 22,069,983 Mb (A_16_P18578628, last deleted), flanked by oligomers at 19,927,491 Mb (A_16_P18573439, first present) and 22,086,798 Mb
(A_16_P18578677, last present). No CNVs are detected for patient B in the same region. B. Representation of the deletions previously reported in
melanoma-NST (ME-NST) and in melanoma (ME) kindreds, in blue and grey lines respectively, in comparison to the deletion detected in patient
A. The status of microsatellite markers and of genes comprised in the region as derived from MLPA is shown. The start nucleotide position for
microsatellites and genes is indicated (UCSC Genome Browser) [16-18].
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cluster, KLHL9, IFNW1, IFNB1, PTPLAD2, FOCAD, MIR491,
SNORA30, MLLT3,MIR4473 andMIR4474 (Figure 2A).
The second case studied, patient B, is a boy developing
melanoma associated to congenital nevi on the head
(17 yr) after astrocytoma (7 yr). Five years later he devel-
oped fatal pleuric rhabdomyosarcoma. His pedigree
lacked neoplastic diseases. No alterations were revealed
by sequence analysis in CDKN2A gene except for the
rs3814960 and rs11515 variants in the 3′UTR and 5′UTR
regions, which are rather common single nucleotide poly-
morphisms (SNPs) in melanoma patients [19]. In addition,
he carried wild type CDK4, MC1R and MITF genes, and a
normal profile of the CDKN2A-CDKN2B region was
shown by MLPA. aCGH analysis showed a normal ratio
profile at the 9p21.3 region (Figure 2A) and revealed copy
number gains on 4p14 and 6q24.3 of uncertain clinical
significance, which deserve further studies and analyses in
other patients with similar diseases (see Additional file 5:
Table S2).
Conclusions
Germ line mutations at CDKN2A locus are generally
inherited founder mutations having a common ancestral
origin, while de novo mutations appear to be exceedingly
rare events [20], thus marking a peculiarity in the genetic
of patient A. Although the precise endpoints of the dele-
tion were not determined here, by aCGH it was shown to
span from 19,934,142 to 22,069,983 Mb, thus being larger
than those previously mapped by Pasmant [3]. In fact,
in addition to the CDKN2A/CDKN2B/CDKN2BAS gene
cluster, the deletion extends in the telomeric end to com-
prise a large region up to theMLLT3 gene.
Similarly to the other deletions detected in association
with melanoma and NST, the deleted region includes
part of the CDKN2BAS gene, which on the contrary is
not always included in the deletions occurring in melan-
oma kindreds lacking NST, as schematized in Figure 2B.
CDKN2BAS gene, or ANRIL (antisense non-coding RNA
in the INK4 locus), consists of 19 exons spanning a re-
gion of 126.3 kb located within the CDKN2B-CDKN2A
gene cluster, and is transcribed in the antisense orientation
in a long non-coding RNA involved in epigenetic silencing
of CDKN2B-CDKN2A locus by polycomb repressive com-
plexes [21]. Genome-wide association studies have identi-
fied SNPs in CDKN2BAS associated with susceptibility
to NST as well as to melanoma [22,23]; interestingly,
CDKN2BAS has been identified as a risk locus also for
other cancers and diseases [24]. Among the other genes
comprised in the deleted region, FOCAD has been shown
deleted in glioma tumors [25]. Furthermore, in patient B,
CGH analysis showed copy number gains on 4p14 and
6q24.3 chromosomal regions involving TCF25 and KLF3
genes respectively, which encode for transcription factors,representing potential candidates for further studies. In
fact, TCF25, has been involved in embryonic development
expressed in brain [26], and KLF3, has been reported to
show rearrangements in different cancer types [27].
Our study shows that 9p21.3 deletion is neither neces-
sary nor sufficient for the NST-melanoma syndrome. Of
note, both patients developed melanoma on their head
after radiotherapy for astrocytoma, thus adding to other
evidence suggesting association of melanoma with expos-
ure to ionizing radiation [28-32]; in addition, the TS of pa-
tient A, who was not treated for NST, did not develop
melanoma, although she carried an identical 9p21.3 dele-
tion (see Additional file 6: Figure S3). It results that young
cancer patients treated with radiotherapy should be con-
sidered at risk for developing melanoma and their pig-
mented lesions should be carefully monitored by expert
clinicians. In fact, although melanoma is a rare disease in
the healthy childhood population, it occurs more fre-
quently as second malignant neoplasm after childhood
cancer [33] and should be closely monitored by regularly
screen in the follow-up of survivors, which have an ap-
proximate 2.5-fold increased risk of melanoma [34]. Fur-
thermore, children with genetic syndromes may have
unique pathophysiologies that necessitate careful evalu-
ation and follow-up of skin alterations, since often derma-
tologists find unusual and atypical correspondences
between clinic and dermoscopic parameters and the histo-
logical ones [35]. A multifaceted approach including a
thorough clinical history, visual examination and dermo-
scopic evaluation of suspicious skin lesions is recom-
mended to increase the sensitivity and specificity for
diagnosing melanoma in these young patients.
Consent
Written informed consent was obtained from the patients’
parents for genetic counselling, DNA analyses, scientific
research and study purposes for all family members. The
consent form was approved by the local ethical committee
(Comitato Etico Centrale IRCCS Lombardia). A copy of
the written consent is available for review by the Editor of
this journal.
Additional files
Additional file 1: Methods.
Additional file 2: Table S1. Primers of the microsatellite markers used
in the study. Start and end positions are reported according to UCSC
Genome Browser (NCBI Build 37, hg19).
Additional file 3: Figure S1. Microsatellite analysis revealing loss of the
paternal allele in patient A and TS. Homozygosity or hemizygosity at
microsatellite loci was analyzed by PCR and amplification products
analyzed with the ABI Prism Peak Scanner Software.
Additional file 4: Figure S2. Results of MLPA of the 9p region in
patient A, TS and parents. Results obtained with MLPA arrays for the
9p21 region ordered according to the genomic location of the probes.
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shown, for patient A and TS in full bars, and for parents in empty bars.
The deletion detected in the two sisters extends from CDKN2B to MLLT3
genes, and includes CDKN2A, MTAP, IFNA1, KLH9, IFNW1, and IFNB1 genes;
in contrast, ELAV2 and TEK centromeric to CDKN2B and GLDC and DOCK8
telomeric to MLLT3 showed normal gene dosage quotients indicating
retention of both gene copies.
Additional file 5: Table S2. List of chromosomal aberrations detected
by aCGH (400K) in patient B not reported in the Database of Genomic
Variants (http://dgv.tcag.ca/dgv/app/home?ref=GRCh37/hg19). CNVs in
non coding regions were detected on 7p12.3, 7q11.22, 19q13.11
chromosomal regions. A large region on 14q11.2 contains genes poorly
characterize functionally. CNVs on 4p14 and 16q24.3 involve genes of
potential interest since they have been involved in the regulation of cell
growth and death.
Additional file 6: Figure S3. Results of array-CGH of the 9p21.3 region
in patient A and her twin sister. aCGH analysis showed an identical
9p21.3 deletion of ~ 2,135 Mb.
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